1887
  1. Home
  2. Eurosurveillance
  3. Volume 29, Issue 45, 07/Nov/2024
  4. Article
Outbreaks Open Access
Like 0
Download

Abstract

After the start of the COVID-19 pandemic, a rapid rise in reported numbers and wide geographic spread of -related invasive infections has been observed globally. However, the contemporary epidemiology of fungaemias in Greece remains unknown. An outbreak of bloodstream infections has been ongoing for almost 3 years in a Greek tertiary care academic hospital, with 89 -driven episodes appearing in five waves every 6–7 months following peaks in colonisation rates by 3–4 months. All isolates clustered in clade I and were genetically related, 84% were fluconazole-resistant and all were non-resistant to amphotericin B and echinocandins, except one pan-echinocandin-resistant isolate ( mutant) recovered from a patient on empiric therapy with anidulafungin. Notably, was in 2023 the most prevalent (34%) cause of candidaemia in our hospital. The accelerated and long-term transmission dynamics of fungaemia underscore the need for rigorous infection control measures, while antifungal stewardship is warranted to contain the selection of echinocandin-resistant isolates.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2024.29.45.2400128
2024-11-07
2024-12-24
/content/10.2807/1560-7917.ES.2024.29.45.2400128
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/29/45/eurosurv-29-45-4.html?itemId=/content/10.2807/1560-7917.ES.2024.29.45.2400128&mimeType=html&fmt=ahah

References

  1. Lyman M, Forsberg K, Sexton DJ, Chow NA, Lockhart SR, Jackson BR, et al. Worsening spread of Candida auris in the United States, 2019 to 2021. Ann Intern Med. 2023;176(4):489-95.  https://doi.org/10.7326/M22-3469  PMID: 36940442 
  2. Kohlenberg A, Monnet DL, Plachouras D, Candida auris survey collaborative group, Candida auris survey collaborative group includes the following national experts. Increasing number of cases and outbreaks caused by Candida auris in the EU/EEA, 2020 to 2021. Euro Surveill. 2022;27(46):2200846.  https://doi.org/10.2807/1560-7917.ES.2022.27.46.2200846  PMID: 36398575 
  3. Witt LS, Howard-Anderson JR, Jacob JT, Gottlieb LB. The impact of COVID-19 on multidrug-resistant organisms causing healthcare-associated infections: a narrative review. JAC Antimicrob Resist. 2022;5(1):dlac130.  https://doi.org/10.1093/jacamr/dlac130  PMID: 36601548 
  4. Theut M, Antsupova V, Andreasen AS, Buhl D, Midttun M, Knudsen JD, et al. [The first two cases of Candida auris in Denmark]. Ugeskr Laeger. 2022;184(16):V10210768. Danish. PMID: 35485779 
  5. Hinrichs C, Wiese-Posselt M, Graf B, Geffers C, Weikert B, Enghard P, et al. Successful control of Candida auris transmission in a German COVID-19 intensive care unit. Mycoses. 2022;65(6):643-9.  https://doi.org/10.1111/myc.13443  PMID: 35419847 
  6. Alshamrani MM, El-Saed A, Mohammed A, Alghoribi MF, Al Johani SM, Cabanalan H, et al. Management of Candida auris outbreak in a tertiary-care setting in Saudi Arabia. Infect Control Hosp Epidemiol. 2021;42(2):149-55.  https://doi.org/10.1017/ice.2020.414  PMID: 32880247 
  7. Prestel C, Anderson E, Forsberg K, Lyman M, de Perio MA, Kuhar D, et al. Candida auris outbreak in a COVID-19 specialty care unit - Florida, July-August 2020. MMWR Morb Mortal Wkly Rep. 2021;70(2):56-7.  https://doi.org/10.15585/mmwr.mm7002e3  PMID: 33444298 
  8. Pan American Health Organization (PAHO). Epidemiological Alert: Candida auris outbreaks in health care services in the context of the COVID-19 pandemic - 6 February 2021. Washington, DC PAHO; 2021. Available from: https://www.paho.org/en/documents/epidemiological-alert-candida-auris-outbreaks-health-care-services-context-covid-19
  9. Henriques J, Mixão V, Cabrita J, Duarte TI, Sequeira T, Cardoso S, et al. Candida auris in intensive care setting: the first case reported in Portugal. J Fungi (Basel). 2023;9(8):837.  https://doi.org/10.3390/jof9080837  PMID: 37623608 
  10. Stanciu AM, Florea D, Surleac M, Paraschiv S, Oțelea D, Tălăpan D, et al. First report of Candida auris in Romania: clinical and molecular aspects. Antimicrob Resist Infect Control. 2023;12(1):91.  https://doi.org/10.1186/s13756-023-01297-x  PMID: 37674189 
  11. Oladele R, Uwanibe JN, Olawoye IB, Ettu AO, Meis JF, Happi CT. Emergence and genomic characterization of multidrug resistant Candida auris in Nigeria, West Africa. J Fungi (Basel). 2022;8(8):787.  https://doi.org/10.3390/jof8080787  PMID: 36012776 
  12. Al-Ramahi JW, Ghanem RA, Sayyouh OH, Al-Jammal D, Said MM, Nasrat S, et al. Report of the first case of Candida auris identified in Jordan. Microbiol Res (Pavia). 2023;14(4):1559-67.  https://doi.org/10.3390/microbiolres14040107 
  13. Allaw F, Kara Zahreddine N, Ibrahim A, Tannous J, Taleb H, Bizri AR, et al. First Candida auris outbreak during a COVID-19 pandemic in a tertiary-care center in Lebanon. Pathogens. 2021;10(2):157.  https://doi.org/10.3390/pathogens10020157  PMID: 33546137 
  14. Fox-Lewis S, Buckwell L, McKinney W, Tang R, Upton G, Francis B, et al. Candida auris: lessons learnt from the first detected case in Aotearoa New Zealand. N Z Med J. 2023;136(1580):78-80.  https://doi.org/10.26635/6965.6222  PMID: 37536315 
  15. Katsiari M, Mavroidi A, Kesesidis N, Palla E, Zourla K, Ntorlis K, et al. Emergence of clonally-related south Asian clade I clinical isolates of Candida auris in a Greek COVID-19 intensive care unit. J Fungi (Basel). 2023;9(2):243.  https://doi.org/10.3390/jof9020243  PMID: 36836357 
  16. Siopi M, Georgiou P-C, Paranos P, Beredaki M-I, Tarpatzi A, Kalogeropoulou E, et al. Increase in candidemia cases and emergence of fluconazole-resistant Candida parapsilosis and C. auris isolates in a tertiary care academic hospital during the COVID-19 pandemic, Greece, 2020 to 2023. Euro Surveill. 2024;29(29):2300661.  https://doi.org/10.2807/1560-7917.ES.2024.29.29.2300661  PMID: 39027938 
  17. Clinical and Laboratory Standards Institute (CLSI). M27: Reference method for broth dilution antifungal susceptibility testing of yeasts. 4th edition. Wayne: CLSI; 2017. Available from: https://clsi.org/media/1897/m27ed4_sample.pdf
  18. Centers for Disease Control and Prevention (CDC). Antifungal susceptibility testing for C. auris. Atlanta: CDC. [Accessed: Feb 2023]. Available from: https://www.cdc.gov/candida-auris/hcp/laboratories/antifungal-susceptibility-testing.html
  19. Arendrup MC, Prakash A, Meletiadis J, Sharma C, Chowdhary A. Comparison of EUCAST and CLSI reference microdilution mics of eight antifungal compounds for Candida auris and associated tentative epidemiological cutoff values. Antimicrob Agents Chemother. 2017;61(6):e00485-17.  https://doi.org/10.1128/AAC.00485-17  PMID: 28416539 
  20. de Groot T, Puts Y, Berrio I, Chowdhary A, Meis JF. Development of Candida auris short tandem repeat typing and its application to a global collection of isolates. mBio. 2020;11(1):e02971-19.  https://doi.org/10.1128/mBio.02971-19  PMID: 31911492 
  21. Asadzadeh M, Mokaddas E, Ahmad S, Abdullah AA, de Groot T, Meis JF, et al. Molecular characterisation of Candida auris isolates from immunocompromised patients in a tertiary-care hospital in Kuwait reveals a novel mutation in FKS1 conferring reduced susceptibility to echinocandins. Mycoses. 2022;65(3):331-43.  https://doi.org/10.1111/myc.13419  PMID: 34953089 
  22. Koukaki E, Rovina N, Tzannis K, Sotiropoulou Z, Loverdos K, Koutsoukou A, et al. Fungal infections in the ICU during the COVID-19 era: descriptive and comparative analysis of 178 patients. J Fungi (Basel). 2022;8(8):881.  https://doi.org/10.3390/jof8080881  PMID: 36012869 
  23. Routsi C, Meletiadis J, Charitidou E, Gkoufa A, Kokkoris S, Karageorgiou S, et al. Epidemiology of candidemia and fluconazole resistance in an ICU before and during the COVID-19 pandemic era. Antibiotics (Basel). 2022;11(6):771.  https://doi.org/10.3390/antibiotics11060771  PMID: 35740177 
  24. Giannitsioti E, Louka C, Mamali V, Kousouli E, Velentza L, Papadouli V, et al. Bloodstream Infections in a COVID-19 non-ICU department: microbial epidemiology, resistance profiles and comparative analysis of risk factors and patients’ outcome. Microorganisms. 2022;10(7):1314.  https://doi.org/10.3390/microorganisms10071314  PMID: 35889033 
  25. Politi L, Vrioni G, Hatzianastasiou S, Lada M, Martsoukou M, Sipsas NV, et al. Candida auris in Greek healthcare facilities: Active surveillance results on first cases and outbreaks from eleven hospitals within Attica region. J Mycol Med. 2024;34(2):101477.  https://doi.org/10.1016/j.mycmed.2024.101477  PMID: 38574412 
  26. Kumar JA, Cadnum JL, Jencson AL, Donskey CJ. Are reduced concentrations of chlorine-based disinfectants effective against Candida auris? Am J Infect Control. 2020;48(4):448-50.  https://doi.org/10.1016/j.ajic.2019.08.027  PMID: 31604622 
  27. Kean R, Sherry L, Townsend E, McKloud E, Short B, Akinbobola A, et al. Surface disinfection challenges for Candida auris: an in-vitro study. J Hosp Infect. 2018;98(4):433-6.  https://doi.org/10.1016/j.jhin.2017.11.015  PMID: 29203448 
  28. Stathi A, Loukou I, Kirikou H, Petrocheilou A, Moustaki M, Velegraki A, et al. Isolation of Candida auris from cystic fibrosis patient, Greece, April 2019. Euro Surveill. 2019;24(29):1.  https://doi.org/10.2807/1560-7917.ES.2019.24.29.1900400  PMID: 31339093 
  29. Ioannou P, Kofteridis DP, Alexakis K, Koutserimpas C, Papakitsou I, Maraki S, et al. Candida species isolation from hospitalized patients with COVID-19-a retrospective study. Diagnostics (Basel). 2022;12(12):3065.  https://doi.org/10.3390/diagnostics12123065  PMID: 36553072 
  30. Papadimitriou-Olivgeris M, Kolonitsiou F, Kefala S, Spiliopoulou A, Aretha D, Bartzavali C, et al. Increased incidence of candidemia in critically ill patients during the coronavirus disease 2019 (COVID-19) pandemic. Braz J Infect Dis. 2022;26(2):102353.  https://doi.org/10.1016/j.bjid.2022.102353  PMID: 35500645 
  31. Boattini M, Pinto MF, Christaki E, Fasciana T, Falces-Romero I, Tofarides A, et al. Multicentre surveillance of Candida species from blood cultures during the SARS-CoV-2 pandemic in southern Europe (CANCoVEU project). Microorganisms. 2023;11(3):560.  https://doi.org/10.3390/microorganisms11030560  PMID: 36985134 
  32. Villanueva-Lozano H, Treviño-Rangel RJ, González GM, Ramírez-Elizondo MT, Lara-Medrano R, Aleman-Bocanegra MC, et al. Outbreak of Candida auris infection in a COVID-19 hospital in Mexico. Clin Microbiol Infect. 2021;27(5):813-6.  https://doi.org/10.1016/j.cmi.2020.12.030  PMID: 33429028 
  33. Dire O, Ahmad A, Duze S, Patel M. Survival of Candida auris on environmental surface materials and low-level resistance to disinfectant. J Hosp Infect. 2023;137:17-23.  https://doi.org/10.1016/j.jhin.2023.04.007  PMID: 37116661 
  34. Welsh RM, Bentz ML, Shams A, Houston H, Lyons A, Rose LJ, et al. Survival, persistence, and isolation of the emerging multidrug-resistant pathogenic yeast Candida auris on a plastic health care surface. J Clin Microbiol. 2017;55(10):2996-3005.  https://doi.org/10.1128/JCM.00921-17  PMID: 28747370 
  35. Bergeron G, Bloch D, Murray K, Kratz M, Parton H, Ackelsberg J, et al. Candida auris colonization after discharge to a community setting: New York City, 2017-2019. Open Forum Infect Dis. 2020;8(1):ofaa620.  https://doi.org/10.1093/ofid/ofaa620  PMID: 33511238 
  36. Biran R, Cohen R, Finn T, Brosh-Nissimov T, Rahav G, Yahav D, et al. Nationwide outbreak of Candida auris infections driven by COVID-19 hospitalizations, Israel, 2021-2022. Emerg Infect Dis. 2023;29(7):1297-301.  https://doi.org/10.3201/eid2907.221888  PMID: 37347492 
  37. de Groot T, Spruijtenburg B, Parnell LA, Chow NA, Meis JF. Optimization and validation of Candida auris short tandem repeat analysis. Microbiol Spectr. 2022;10(5):e0264522.  https://doi.org/10.1128/spectrum.02645-22  PMID: 36190407 
  38. Adams E, Quinn M, Tsay S, Poirot E, Chaturvedi S, Southwick K, et al. Candida auris in healthcare facilities, New York, USA, 2013-2017. Emerg Infect Dis. 2018;24(10):1816-24.  https://doi.org/10.3201/eid2410.180649  PMID: 30226155 
  39. Chen J, Tian S, Han X, Chu Y, Wang Q, Zhou B, et al. Is the superbug fungus really so scary? A systematic review and meta-analysis of global epidemiology and mortality of Candida auris. BMC Infect Dis. 2020;20(1):827.  https://doi.org/10.1186/s12879-020-05543-0  PMID: 33176724 
  40. Centers for Disease Control and Prevention (CDC). Clinical treatment of C. auris infections. Atlanta: CDC. [Accessed: Feb 2023]. Available from: https://www.cdc.gov/candida-auris/hcp/clinical-care/index.html
  41. Codda G, Willison E, Magnasco L, Morici P, Giacobbe DR, Mencacci A, et al. In vivo evolution to echinocandin resistance and increasing clonal heterogeneity in Candida auris during a difficult-to-control hospital outbreak, Italy, 2019 to 2022. Euro Surveill. 2023;28(14):2300161.  https://doi.org/10.2807/1560-7917.ES.2023.28.14.2300161  PMID: 37022211 
  42. Spruijtenburg B, Ahmad S, Asadzadeh M, Alfouzan W, Al-Obaid I, Mokaddas E, et al. Whole genome sequencing analysis demonstrates therapy-induced echinocandin resistance in Candida auris isolates. Mycoses. 2023;66(12):1079-86.  https://doi.org/10.1111/myc.13655  PMID: 37712885 
  43. COVID-19. The spread of the disease in Greece. Athens: iMEdD Lab. [Accessed: 10 Jan 2024]. Available from: https://lab.imedd.org/covid19/?lang=en
Candida auris fungaemia outbreak in a tertiary care academic hospital and emergence of a pan-echinocandin resistant isolate, Greece, 2021 to 2023
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Joseph+Meletiadis&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Meletiadis Joseph</a>, <a href="/search?value1=Maria+Siopi&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Siopi Maria</a>, <a href="/search?value1=Bram+Spruijtenburg&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Spruijtenburg Bram</a>, <a href="/search?value1=Panagiota-Christina+Georgiou&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Georgiou Panagiota-Christina</a>, <a href="/search?value1=Maria+Kostoula&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kostoula Maria</a>, <a href="/search?value1=Sophia+Vourli&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Vourli Sophia</a>, <a href="/search?value1=Frantzeska+Frantzeskaki&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Frantzeskaki Frantzeska</a>, <a href="/search?value1=Elisabeth+Paramythiotou&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Paramythiotou Elisabeth</a>, <a href="/search?value1=Jacques+F+Meis&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Meis Jacques F</a>, <a href="/search?value1=Iraklis+Tsangaris&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Tsangaris Iraklis</a>, <a href="/search?value1=Spyros+Pournaras&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Pournaras Spyros</a></span>. Candida auris fungaemia outbreak in a tertiary care academic hospital and emergence of a pan-echinocandin resistant isolate, Greece, 2021 to 2023. <a href="/content/ecdc">Euro Surveill.</a> 2024;29(45):pii=2400128. <a href="https://doi.org/10.2807/1560-7917.ES.2024.29.45.2400128" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2024.29.45.2400128</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 24 Feb 2024;&nbsp;&nbsp; <span class="generated">Accepted</span>: 29 May 2024 </span> </p>
/content/10.2807/1560-7917.ES.2024.29.45.2400128
/content/10.2807/1560-7917.ES.2024.29.45.2400128
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error